An Extraordinary General Meeting in Arctic Bioscience AS will be held Tuesday 11
November 2025 at 10:00 (CET), as a digital meeting.
The agenda of the meeting is election of a new auditor for the Company. The
elected auditor, PwC, has informed Arctic Bioscience AS of corporate
reorganization that will result in a portion of their business, including
partners, employees and clients, being moved to a wholly owned subsidiary.
Arctic Bioscience AS is one of the clients that has been moved to the wholly
owned subsidiary. The move does not entail any changes to the services provided.
The reorganization of PwC therefore only has the practical effect that PwC's
subsidiary, PwC Assurance AS, must be elected as auditor instead of PwC AS. See
notice for more information.
Shareholders are encouraged to cast their votes in advance of the General
Meeting or grant the Chair of the Board a proxy, with or without voting
instructions.
Deadline for registration of attendance, advance votes, proxy or instructions is
7 November 2025 at 16:00 (CET). For attendance to the live event, please follow
the instructions in the notice.
For further information, see the attached Notice of the Extraordinary General
Meeting, which can also be accessed from the company's website (https://arctic
-bioscience.com/investors/general-meetings/).
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Christer L. Valderhaug
CEO
Phone: +47 920 84 601
E-mail: christer@arctic-bioscience.com
Jone R. Slinning
CFO
Mobile: +47 948 75 469
E-mail: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.